Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage

The Case Against Antibody Drug Conjugates for Patients With Lung Cancers

Corey Langer, MD


At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Corey Langer, MD, Abramson Cancer Center, Philadelphia, Pennsylvania, argued that antibody drug conjugates are not ready to replace TROP-2 inhibitors as the standard of care for patients with lung cancers. 


Source: 

Langer C. Debate: ADCs: The new emperor or the emperor’s new clothes. Presented at Great Debates & Updates in Lung Cancer; April 27-28, 2024; New York, NY.

© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates. 

Advertisement

Advertisement

Advertisement

Advertisement